Document is current

Article History

Received: 12 July 2022

Accepted: 25 February 2023

First Online: 31 March 2023

Declarations

:

: The Charité – Universitaetsmedizin Berlin, Germany, local Ethics Committee approved the retrospective chart review of routinely assessed clinical parameters (approval no. EA2/112/19).All patient data routinely collected and stored in the context of hospital treatment were anonymized for research purposes before evaluation. The information has been treated following the Data Protection Act 2017 and the General Data Protection Regulation (GDPR; 33). For the retrospective chart review, patients’ formal consent was not required from the local Ethics Committee of the Charité – Universitaetsmedizin Berlin, Germany.

: For a retrospective chart review based on routinely assessed clinical parameters, patients’ consent for publication was not required from the local Ethics Committee of the Charité – Universitaetsmedizin Berlin, Germany.

: The authors SA and CJ declare that they have no competing interests. CC has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Mindpax, LB Pharma, and Quantic.